Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice

Paediatrics and Child Health

Volumn 11, Issue 1, 2006, Pages 19-23

  Bellavance, Marc ^a,d   Rohlicek, Charles V ^a   Bigras, Jean Luc ^b   Côté, Jean Marc ^c   Paquet, Marc ^d   Lebel, Marc H ^b   Mackie, Andrew S ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Congenital heart disease; Guidelines; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CANADA; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DOSE RESPONSE; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK REDUCTION; TREATMENT OUTCOME;

EID: 33644899968     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol 1973;98:289-300.
2. Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52.
3. Fixler DE. Respiratory syncytial virus infection in children with congenital heart disease: A review. Pediatr Cardiol 1996;17:163-8.
4. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
5. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-54.
6. Moler FW, Khan AS, Meliones JN, Custer JR, Palmisano J, Shope TC. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: A recent experience. Crit Care Med 1992;20:1406-13.
7. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: Postoperative course and outcome. Crit Care Med 1999;27:1974-81.
8. Feltes TF, Cabalka AK, Meissner HC, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
9. National Advisory Committee on Immunization. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab). Can Commun Dis Rep 2003;29:1-15.
10. Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Use of palivizumab in children with congenital heart disease. Paediatr Child Health 2003;8:631-3.
11. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11.
12. Synagis product manual. MedImmune Inc, September 14, 2003.
13. Mackie AS, Gauvreau K, Newburger JW, Mayer JE, Erickson LC. Risk factors for readmission after neonatal cardiac surgery. Ann Thorac Surg 2004;78:1972-8.
14. Macartney KK, Gorelick MH, Manning ML, Hodinka RL, Bell LM. Nosocomial respiratory syncytial virus infections: The cost-effectiveness and cost-benefit of infection control. Pediatrics 2000;106:520-6.
15. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003;112:1442-6.
16. Mullins JA, Lamonte AC, Bresee JS, Anderson LJ. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J 2003;22:857-62.
17. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-24.
18. Institut de la Statistique du Québec. Naissances et taux de natalité. Québec, 1900-2004. 〈http://www.stat.gouv.qc.ca/ donstat/societe/demographie/naisn_deces/naissance/401.htm〉 (Version current at January 11, 2006).
19. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004;89:961-5.